User menu

Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?

Bibliographic reference Luyckx, Mathieu. Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?. In: PLoS One, Vol. 11, no.1, p. 1-12 (january 2016)
Permanent URL
  1. R Siegel, CA: a cancer journal for clinicians, 62, 10 (2012)
  2. A Jemal, CA: a cancer journal for clinicians, 58, 71 (2008)
  3. Bristow R. E., Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis, 10.1200/jco.20.5.1248
  4. McGuire William P., Hoskins William J., Brady Mark F., Kucera Paul R., Partridge Edward E., Look Katherine Y., Clarke-Pearson Daniel L., Davidson Martin, Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer, 10.1056/nejm199601043340101
  5. Vergote Ignace, Tropé Claes G., Amant Frédéric, Kristensen Gunnar B., Ehlen Tom, Johnson Nick, Verheijen René H.M., van der Burg Maria E.L., Lacave Angel J., Panici Pierluigi Benedetti, Kenter Gemma G., Casado Antonio, Mendiola Cesar, Coens Corneel, Verleye Leen, Stuart Gavin C.E., Pecorelli Sergio, Reed Nick S., Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer, 10.1056/nejmoa0908806
  6. TW Burke, Obstetrics and gynecology clinics of North America, 21, 167 (1994)
  7. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J L, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin., 10.1200/jco.1991.9.3.389
  8. Naumann R. Wendel, Coleman Robert L., Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer : , 10.2165/11591720-000000000-00000
  9. Alberts David S., Liu P.Y., Wilczynski Sharon P., Clouser Mary C., Lopez Ana Maria, Michelin David P., Lanzotti Victor J., Markman Maurie, Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200), 10.1016/j.ygyno.2007.08.075
  10. Pujade-Lauraine Eric, Wagner Uwe, Aavall-Lundqvist Elisabeth, Gebski Val, Heywood Mark, Vasey Paul A., Volgger Birgit, Vergote Ignace, Pignata Sandro, Ferrero Annamaria, Sehouli Jalid, Lortholary Alain, Kristensen Gunnar, Jackisch Christian, Joly Florence, Brown Chris, Le Fur Nathalie, du Bois Andreas, Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse, 10.1200/jco.2009.25.7519
  11. Luyckx Mathieu, Leblanc Eric, Filleron Thomas, Morice Philippe, Darai Emile, Classe Jean-Marc, Ferron Gwenaël, Stoeckle Eberhard, Pomel Christophe, Vinet Bénédicte, Chereau Elisabeth, Bergzoll Cécile, Querleu Denis, Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice : A Retrospective French Multicentric Study, 10.1097/igc.0b013e31826a3559
  12. J Esquivel, G Chir, 20, 81 (1999)
  13. du Bois A., A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer, 10.1093/jnci/djg036
  14. Pfisterer Jacobus, Weber Béatrice, Reuss Alexander, Kimmig Rainer, du Bois Andreas, Wagner Uwe, Bourgeois Hugues, Meier Werner, Costa Serban, Blohmer Jens-Uwe, Lortholary Alain, Olbricht Sigrid, Stähle Anne, Jackisch Christian, Hardy-Bessard Anne-Claire, Möbus Volker, Quaas Jens, Richter Barbara, Schröder Willibald, Geay Jean-François, Lück Hans-Joachim, Kuhn Walther, Meden Harald, Nitz Ulrike, Pujade-Lauraine Eric, Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO, 10.1093/jnci/djj296
  15. du Bois Andreas, Weber Beatrice, Rochon Justine, Meier Werner, Goupil Alain, Olbricht Sigrid, Barats Jean-Claude, Kuhn Walther, Orfeuvre Hubert, Wagner Uwe, Richter Barbara, Lueck Hans-Joachim, Pfisterer Jacobus, Costa Serban, Schroeder Willibald, Kimmig Rainer, Pujade-Lauraine Eric, Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, 10.1200/jco.2005.03.2938
  16. du Bois Andreas, Reuss Alexander, Pujade-Lauraine Eric, Harter Philipp, Ray-Coquard Isabelle, Pfisterer Jacobus, Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials : By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO), 10.1002/cncr.24149
  17. Harter Philipp, Bois Andreas du, Hahmann Maik, Hasenburg Annette, Burges Alexander, Loibl Sibylle, Gropp Martina, Huober Jens, Fink Daniel, Schröder Willibald, Muenstedt Karsten, Schmalfeldt Barbara, Emons Guenter, Pfisterer Jacobus, Wollschlaeger Kerstin, Meerpohl Hans-Gerd, Breitbach Georg-Peter, Tanner Berno, Sehouli Jalid, Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial, 10.1245/s10434-006-9058-0
  18. Alexandre J., Ray-Coquard I., Selle F., Floquet A., Cottu P., Weber B., Falandry C., Lebrun D., Pujade-Lauraine E., , Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience, 10.1093/annonc/mdq257
  19. Tagliabue Elda, Agresti Roberto, Carcangiu Maria Luisa, Ghirelli Cristina, Morelli Daniele, Campiglio Manuela, Martel Maritza, Giovanazzi Riccardo, Greco Marco, Balsari Andrea, Ménard Sylvie, Role of HER2 in wound-induced breast carcinoma proliferation, 10.1016/s0140-6736(03)14112-8
  20. Singer C. F, Hudelist G., Fuchs E.-M., Kostler W., Fink-Retter A., Gschwantler-Kaulich D., Gnant M., Lamm W., Rudas M., Czerwenka K., Kubista E., Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells, 10.1677/erc-08-0065
  21. P Impellizzeri, European journal of pediatric surgery: official journal of Austrian Association of Pediatric Surgery [et al] = Zeitschrift fur Kinderchirurgie (2013)
  22. Wang Yue, Niu Xiu Long, Qu Ye, Wu Jian, Zhu Ya Qin, Sun Wei Jia, Li Ling Zhi, Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells, 10.1016/j.canlet.2010.02.019
  23. Wang Yue, Qu Ye, Niu Xiu Long, Sun Wei Jia, Zhang Xiao Lei, Li Ling Zhi, Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells, 10.1016/j.cyto.2011.06.005
  24. Touboul Cyril, Lis Raphael, Al Farsi Halema, Raynaud Christophe M, Warfa Mohamed, Althawadi Hamda, Mery Eliane, Mirshahi Massoud, Rafii Arash, Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model, 10.1186/1479-5876-11-28
  25. Lis Raphael, Touboul Cyril, Raynaud Christophe M., Malek Joel A., Suhre Karsten, Mirshahi Massoud, Rafii Arash, Mesenchymal Cell Interaction with Ovarian Cancer Cells Triggers Pro-Metastatic Properties, 10.1371/journal.pone.0038340